To read the full story, subscribe or sign in.

Junshi steps up efforts in Europe by filing for the NDA of toripalimab

Nov. 16, 2022

Shanghai Junshi Biosciences Co. Ltd. has submitted a new drug application (NDA) for its anti-PD-1 monoclonal antibody toripalimab to the European Medicines Agency, which marks the first NDA filing of toripalimab in Europe.

BioWorld Regulatory Cancer Europe China EMA

Today's news in brief

BioWorld

BioWorld briefs for Feb. 25, 2025.

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 24, 2025

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...

Evo 2 AI allows genome and epigenome modeling of all life domains

BioWorld MedTech

A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA...